{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:36:02Z","timestamp":1790386562001,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011498","name":"Shaoxing Bureau of Science and Technology","doi-asserted-by":"publisher","award":["2021YFSY0007"],"award-info":[{"award-number":["2021YFSY0007"]}],"id":[{"id":"10.13039\/501100011498","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["ZYYC20013"],"award-info":[{"award-number":["ZYYC20013"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22105137"],"award-info":[{"award-number":["22105137"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172634"],"award-info":[{"award-number":["82172634"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2018HXBH046"],"award-info":[{"award-number":["2018HXBH046"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2020HXBH051"],"award-info":[{"award-number":["2020HXBH051"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2020M683324"],"award-info":[{"award-number":["2020M683324"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.xcrm.2022.100741","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T10:46:14Z","timestamp":1662979574000},"page":"100741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in triple-negative breast cancer"],"prefix":"10.1016","volume":"3","author":[{"given":"Xueyan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2926-3440","authenticated-orcid":false,"given":"Hubing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2022.100741_bib1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/cncr.23243","article-title":"The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004","volume":"112","author":"Brown","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2022.100741_bib2","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2022.100741_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mds195","article-title":"Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents","volume":"23","author":"Andr\u00e9","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2022.100741_bib4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.19.00904","article-title":"Phase III trial of adjuvant capecitabine after standard neo-\/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM\/2003-11_CIBOMA\/2004-01)","volume":"38","author":"Lluch","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2022.100741_bib5","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1200\/JCO.2014.55.2984","article-title":"Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer","volume":"32","author":"O'Shaughnessy","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2022.100741_bib6","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2022.100741_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"Sikov","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2022.100741_bib8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2022.100741_bib9","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3390\/cancers12040916","article-title":"The landscape of targeted therapies in TNBC","volume":"12","author":"Vagia","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2022.100741_bib10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.xcrm.2022.100741_bib11","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nrc1503","article-title":"Targeting the mitogen-activated protein kinase cascade to treat cancer","volume":"4","author":"Sebolt-Leopold","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2022.100741_bib12","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/annonc\/mdm522","article-title":"MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer","volume":"19","author":"Eralp","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2022.100741_bib13","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1158\/1078-0432.CCR-15-1125","article-title":"RAS\/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1\/PD-L1 immune checkpoint inhibitors","volume":"22","author":"Loi","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2022.100741_bib14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.annonc.2021.01.065","article-title":"A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis","volume":"32","author":"Brufsky","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2022.100741_bib15","first-page":"1747","article-title":"Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression","volume":"8","author":"Adeyinka","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2022.100741_bib16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2022.100741_bib17","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2022.100741_bib18","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1158\/1078-0432.CCR-11-0563","article-title":"Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements","volume":"18","author":"Hayes","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2022.100741_bib19","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1200\/JCO.2015.63.2471","article-title":"Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer","volume":"33","author":"Corcoran","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2022.100741_bib20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cell.2012.02.053","article-title":"Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer","volume":"149","author":"Duncan","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2022.100741_bib21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/2159-8290.CD-16-0653","article-title":"Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex","volume":"7","author":"Zawistowski","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2022.100741_bib22","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/nature04106","article-title":"A heterodimeric complex that promotes the assembly of mammalian 20S proteasomes","volume":"437","author":"Hirano","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2022.100741_bib23","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1128\/MCB.00216-10","article-title":"PAC1 gene knockout reveals an essential role of chaperone-mediated 20S proteasome biogenesis and latent 20S proteasomes in cellular homeostasis","volume":"30","author":"Sasaki","year":"2010","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2022.100741_bib24","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/bioinformatics\/btr709","article-title":"Robust rank aggregation for gene list integration and meta-analysis","volume":"28","author":"Kolde","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2022.100741_bib25","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/annonc\/mdz133","article-title":"Targeting the PI3-kinase pathway in triple-negative breast cancer","volume":"30","author":"Pascual","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2022.100741_bib26","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.drudis.2019.09.001","article-title":"PI3K\/AKT\/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges","volume":"24","author":"Khan","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.xcrm.2022.100741_bib27","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.xcrm.2022.100741_bib28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","article-title":"AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity","volume":"19","author":"Chandarlapaty","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2022.100741_bib29","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","article-title":"mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling","volume":"1","author":"Rodrik-Outmezguine","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2022.100741_bib30","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.18632\/oncotarget.14009","article-title":"Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS\/BRAF mutant colorectal cancer cells","volume":"8","author":"Song","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2022.100741_bib31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41581-019-0148-1","article-title":"The ubiquitin-proteasome system in kidney physiology and disease","volume":"15","author":"Meyer-Schwesinger","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.xcrm.2022.100741_bib32","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1021\/acschemneuro.5b00068","article-title":"Proteasome inhibition augments new protein accumulation early in long-term synaptic plasticity and rescues adverse Abeta effects on protein synthesis","volume":"6","author":"Haynes","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.xcrm.2022.100741_bib33","doi-asserted-by":"crossref","first-page":"441","DOI":"10.14348\/molcells.2017.0115","article-title":"Crosstalk and interplay between the ubiquitin-proteasome system and autophagy","volume":"40","author":"Ji","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2022.100741_bib34","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.aax3769","article-title":"Cellular quality control by the ubiquitin-proteasome system and autophagy","volume":"366","author":"Pohl","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2022.100741_bib35","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1080\/15548627.2019.1596477","article-title":"Proteasome dysfunction induces excessive proteome instability and loss of mitostasis that can be mitigated by enhancing mitochondrial fusion or autophagy","volume":"15","author":"Tsakiri","year":"2019","journal-title":"Autophagy"},{"key":"10.1016\/j.xcrm.2022.100741_bib36","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2022.100741_bib37","doi-asserted-by":"crossref","first-page":"8736","DOI":"10.1158\/0008-5472.CAN-10-0902","article-title":"Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells","volume":"70","author":"Gopal","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2022.100741_bib38","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-11-3747","article-title":"MEK inhibition leads to PI3K\/AKT activation by relieving a negative feedback on ERBB receptors","volume":"72","author":"Turke","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2022.100741_bib39","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1158\/0008-5472.CAN-08-3389","article-title":"Basal subtype and MAPK\/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition","volume":"69","author":"Mirzoeva","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2022.100741_bib40","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/1878-0261.12102","article-title":"MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701","volume":"11","author":"Chen","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.xcrm.2022.100741_bib41","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1158\/1535-7163.MCT-09-0300","article-title":"Combination of EGFR and MEK1\/2 inhibitor shows synergistic effects by suppressing EGFR\/HER3-dependent AKT activation in human gastric cancer cells","volume":"8","author":"Yoon","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.xcrm.2022.100741_bib42","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1158\/1078-0432.CCR-09-0317","article-title":"In\u00a0vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models","volume":"15","author":"Hoeflich","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2022.100741_bib43","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.4161\/cbt.8.21.9844","article-title":"High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)","volume":"8","author":"Meng","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.xcrm.2022.100741_bib44","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1158\/2159-8290.CD-14-0049","article-title":"Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors","volume":"4","author":"Levy","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2022.100741_bib45","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1158\/2159-8290.CD-13-0397","article-title":"Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors","volume":"3","author":"Strohecker","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2022.100741_bib46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40880-017-0219-2","article-title":"Autophagy and multidrug resistance in cancer","volume":"36","author":"Li","year":"2017","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.xcrm.2022.100741_bib47","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.4161\/auto.5.8.9842","article-title":"Autophagy-mediated chemosensitization in cancer cells by fullerene C60 nanocrystal","volume":"5","author":"Zhang","year":"2009","journal-title":"Autophagy"},{"key":"10.1016\/j.xcrm.2022.100741_bib48","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/ijc.25771","article-title":"Autophagy-mediated chemosensitization by cysteamine in cancer cells","volume":"129","author":"Wan","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.xcrm.2022.100741_bib49","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1038\/s41388-019-0675-z","article-title":"Proteasome inhibition boosts autophagic degradation of ubiquitinated-AGR2 and enhances the antitumor efficiency of bevacizumab","volume":"38","author":"Wang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2022.100741_bib50","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2022.100741_bib51","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clml.2019.03.015","article-title":"Oral MEK 1\/2 inhibitor trametinib in combination with AKT inhibitor GSK2141795 in patients with acute myeloid leukemia with RAS mutations: a phase II study","volume":"19","author":"Ragon","year":"2019","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.xcrm.2022.100741_bib52","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1158\/1078-0432.CCR-11-2381","article-title":"The clinical effect of the dual-targeting strategy involving PI3K\/AKT\/mTOR and RAS\/MEK\/ERK pathways in patients with advanced cancer","volume":"18","author":"Shimizu","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2022.100741_bib53","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/s10637-015-0212-z","article-title":"Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer","volume":"33","author":"Do","year":"2015","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.xcrm.2022.100741_bib54","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00280-020-04038-8","article-title":"Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1\/MEK2 inhibitor trametinib in patients with solid tumors","volume":"85","author":"Tolcher","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.xcrm.2022.100741_bib55","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.4161\/auto.25573","article-title":"A novel crosstalk between two major protein degradation systems: regulation of proteasomal activity by autophagy","volume":"9","author":"Wang","year":"2013","journal-title":"Autophagy"},{"key":"10.1016\/j.xcrm.2022.100741_bib56","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/cdd.2008.81","article-title":"The unfolded protein response regulator GRP78\/BiP is required for endoplasmic reticulum integrity and stress-induced autophagy in mammalian cells","volume":"15","author":"Li","year":"2008","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.xcrm.2022.100741_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejphar.2016.08.026","article-title":"Associations between autophagy, the ubiquitin-proteasome system and endoplasmic reticulum stress in hypoxia-deoxygenation or ischemia-reperfusion","volume":"791","author":"Fan","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.xcrm.2022.100741_bib58","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3892\/mmr.2015.4599","article-title":"Induction of autophagy by the MG132 proteasome inhibitor is associated with endoplasmic reticulum stress in MCF7 cells","volume":"13","author":"Bao","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.xcrm.2022.100741_bib59","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cell.2014.11.006","article-title":"Metabolic control of autophagy","volume":"159","author":"Galluzzi","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2022.100741_bib60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/path.2697","article-title":"Autophagy: cellular and molecular mechanisms","volume":"221","author":"Glick","year":"2010","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.xcrm.2022.100741_bib61","first-page":"3174","article-title":"Heterogeneity of tumor cells from a single mouse mammary tumor","volume":"38","author":"Dexter","year":"1978","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2022.100741_bib62","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/nprot.2012.086","article-title":"The ribosome profiling strategy for monitoring translation in\u00a0vivo by deep sequencing of ribosome-protected mRNA fragments","volume":"7","author":"Ingolia","year":"2012","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2022.100741_bib63","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.7150\/thno.35033","article-title":"Survey of the translation shifts in hepatocellular carcinoma with ribosome profiling","volume":"9","author":"Zou","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.xcrm.2022.100741_bib64","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1158\/1055-9965.EPI-19-0469","article-title":"Immune profiles of tumor microenvironment and clinical prognosis among women with triple-negative breast cancer","volume":"28","author":"Deng","year":"2019","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.xcrm.2022.100741_bib65","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nbt.3519","article-title":"Near-optimal probabilistic RNA-seq quantification","volume":"34","author":"Bray","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2022.100741_bib66","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2022.100741_bib67","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nbt.3192","article-title":"Spatial reconstruction of single-cell gene expression data","volume":"33","author":"Satija","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2022.100741_bib68","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41467-020-15523-2","article-title":"SciBet as a portable and fast single cell type identifier","volume":"11","author":"Li","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100741_bib69","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s13059-014-0554-4","article-title":"MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens","volume":"15","author":"Li","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2022.100741_bib70","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12859-016-1015-8","article-title":"BAGEL: a computational framework for identifying essential genes from pooled library screens","volume":"17","author":"Hart","year":"2016","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2022.100741_bib71","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379122002907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379122002907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:51:48Z","timestamp":1762987908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379122002907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":71,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2666379122002907"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2022.100741","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2022.100741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"100741"}}